Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.My back ground story is here:

Saturday, April 23, 2011

Blood clot risk higher in newer birth control pills

Ladies, be careful out there, ask your doctor for the latest.

Women who are using a newer version of birth control that contains the hormone drospirenone have a higher risk of serious blood clot, according to two studies published in the online version of the British Medical Journal.

Drospirenone is found in birth control pills such as Ocella, Yasmin and Yaz.

The studies found that drospirenone has two to three times more risk of blood clots compared with birth control pills containing an older form of a progestin hormone called levonorgestrel. Dr Susan Jick, lead authors said that these findings “provide further evidence that levonorgestrel pills appear to be a safer choice” pertaining to blood clots.
Drug makers dispute the findings, saying the studies are flawed.

The research, led in the U.S. by Jick from the Boston University School of Medicine, used information from United States medical claims data and a United Kingdom research database.

In the U.S., the study reported that in one year, there are 30.8 blood clots per 100,000 women using the birth control containing drospirenone. That rate was lower with 12.5 blood clots for the older birth control pills using levonorgestrel.

"What’s important is that the risk is quite low," Jick said. "30 in 100,000 women is not very many blood clots. It is not that common, but it does happen more in drospirenone than levonorgestrel."

In the U.K., the yearly rates for blood clots were 23 clots per 100,000 women using the drospirenone pill and 9.1 for levonorgestrel.

"There is a risk no matter which oral contraceptive you choose to take," Jick said. "The risk appears higher in drospirenone, than levonorgesterel. Users should just be aware when they’re making a choice that there is a higher risk than the other."

Bayer, the maker of Yaz, challenged the study's methodology and the databases used, saying that they “provide less reliable conclusions than are available from existing scientific evidence.”

“Given the already large and robust scientific body of evidence, in Bayer's opinion, these studies do not change the overall assessment about the safety of Bayer's oral contraceptives.” The company said that the blood clot risk of using contraceptives that contain drospirenone is the same as those in the older birth control pills.

According to Bloomberg News, 6,850 lawsuits were pending in the U.S. as of February 1 over alleged injuries and deaths as a result of the use of Yasmin, Yaz, or generic versions of the drugs.

Physicians cautioned against making knee-jerk reactions to the findings:

– Dr. Jill Rabin, chief of ambulatory care, obstetrics and gynecology at Long Island Jewish Medical Center in New York told WebMD, “These are strong studies, but they will not change the way I practice except that this information will be part of my conversation with patients,”

– André Lalonde, vice-president of the Society of Obstetricians and Gynecologists of Canada, cautioned against jumping to conclusions. In the Globe and Mail, he said: “Each time a new product comes out, we see this – it’s the new pill effect. Risks and complications are always greatest in new patients, much higher than those who have used the same product for a long time."

Update on Apr. 23 Read about comments on the BMJ article. They use lots of big words.

No comments:

Post a Comment